Hemodynamic effects of sotatercept administration in pulmonary hypertension- Insights from remote monitoring.

Although there has been considerable momentum in the field of pulmonary arterial hypertension (PAH) over the past few decades, it remains an incurable disease. Sotatercept is a novel agent that favors pro-apoptotic pathways within the pulmonary artery by way of complex signaling. This unique remodeling mechanism is distinct from traditional vasodilator therapy, as it attempts to address the underpinning pathophysiology of PAH. It was recently approved as an adjunct to traditional vasodilator therapies in non-low risk patients. We describe our early hemodynamic experience with Sotatercept in a series of patients implanted with a pulmonary artery sensor system (CardioMEMS™). Through weekly remote transmissions, we describe the rapid hemodynamic improvement observed in our cohort.